Tipifarnib in Treating Patients With Advanced Hematologic Cancer

NCT ID: NCT00005967

Last Updated: 2013-02-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-08-31

Brief Summary

Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Detailed Description

OBJECTIVES:

I. Determine the relationship between tipifarnib dose and inhibition of farnesylation in malignant cells of patients with advanced hematologic malignancies.

II. Determine the safety profile of this drug in this patient population. III. Determine the clinical activity of this drug in these patients.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 4 dose levels.

Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.

Conditions

Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm I

Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.

Group Type: EXPERIMENTAL

tipifarnib

Intervention Type: DRUG

Interventions

tipifarnib

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed hematologic malignancy refractory to standard therapy or for which no known effective therapy exists

• Hodgkin's or non-Hodgkin's lymphoma

• Known bone marrow involvement
• Acute myeloid leukemia
• Chronic myelogenous leukemia

• Chronic phase

• No significant symptoms after treatment
• No features of accelerated phase or blastic phase
• Accelerated phase

• WBC difficult to control with conventional busulfan or hydroxyurea in terms of dose requirement or shortening of intervals between courses
• Rapid doubling of WBC (less than 5 days)
• At least 10% blasts in blood or marrow
• At least 20% blasts plus promyelocytes in blood or marrow
• At least 20% basophils plus eosinophils in blood
• Anemia or thrombocytopenia unresponsive to busulfan or hydroxyurea
• Persistent thrombocytosis
• Additional chromosome changes
• Increasing splenomegaly
• Development of chloromas or myelofibrosis
• Blastic phase

• At least 30% blasts plus promyelocytes in blood or bone marrow
• Acute lymphoblastic leukemia
• Chronic lymphocytic leukemia
• Myelodysplastic syndromes

• Refractory anemia with excess blasts (RAEB)
• Chronic myelomonocytic leukemia
• RAEB in transformation
• Multiple myeloma
• Chronic myeloproliferative diseases including, but not limited to, myelofibrosis with myeloid metaplasia
• Measurable or evaluable disease documented by radiographic, hematologic, bone marrow, or clinical examination parameters
• Refusal of allogeneic bone marrow transplantation allowed

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• Karnofsky 60-100%

Hepatic:

• Bilirubin no greater than 1.5 mg/dL
• Albumin at least 2.5 g/dL

Renal:

• Creatinine less than 2.0 mg/dL

Other:

• No other uncontrolled medical disorder
• No active inflammatory bowel disease, ileus, or other chronic malabsorption syndromes
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 2 months after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• At least 4 weeks since prior immunotherapy

Chemotherapy:

• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)
• At least 3 days since prior hydroxyurea

Endocrine therapy:

• At least 4 weeks since prior systemic steroids for multiple myeloma

Radiotherapy:

• At least 4 weeks since prior radiotherapy

Surgery:

• No prior total gastrectomy or total ileocolectomy

Other:

• No prior tipifarnib
• No concurrent proton pump inhibitors (e.g., omeprazole)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Todd M. Zimmerman, MD

Role: STUDY_CHAIR

University of Chicago

Locations

University of Chicago Cancer Research Center

Chicago, Illinois, United States

Countries

United States

References

Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 1;22(23):4816-22. doi: 10.1200/JCO.2004.03.200.

Reference Type: RESULT

PMID: 15570084 (View on PubMed)

Other Identifiers

UCCRC-10294

Identifier Type: -

Identifier Source: secondary_id

NCI-42

Identifier Type: -

Identifier Source: secondary_id

CDR0000067950

Identifier Type: REGISTRY

Identifier Source: secondary_id

NCI-2012-02342

Identifier Type: -

Identifier Source: org_study_id